| 46.42 2.71 (6.2%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 58.71 |
1-year : | 68.57 |
| Resists | First : | 50.27 |
Second : | 58.71 |
| Pivot price | 45.01  |
|||
| Supports | First : | 45.4 |
Second : | 42.4 |
| MAs | MA(5) : | 44.23 |
MA(20) : | 46.08 |
| MA(100) : | 39.13 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.5 |
D(3) : | 19.7 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 93.76 | Low : | 27.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PCVX ] has closed below upper band by 22.6%. Bollinger Bands are 26.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 46.57 - 46.8 | 46.8 - 47 |
| Low: | 43.28 - 43.53 | 43.53 - 43.76 |
| Close: | 45.99 - 46.42 | 46.42 - 46.81 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Tue, 16 Dec 2025
Vaxcyte: Financial Durability And The Case For Disruption (NASDAQ:PCVX) - Seeking Alpha
Sun, 14 Dec 2025
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Sat, 13 Dec 2025
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Fri, 12 Dec 2025
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Thu, 11 Dec 2025
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension - Yahoo Finance
Wed, 10 Dec 2025
Vaxcyte, Inc. $PCVX Stake Increased by Diadema Partners LP - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 131 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 110.4 (%) |
| Shares Short | 10,300 (K) |
| Shares Short P.Month | 8,570 (K) |
| EPS | -4.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.1 % |
| Return on Equity (ttm) | -20.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -542 (M) |
| Levered Free Cash Flow | -381 (M) |
| PE Ratio | -9.58 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|